Salarius Pharmaceuticals announced on September 4, 2025, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement.
The company is actively working towards regaining compliance with all Nasdaq continued listing standards by October 20, 2025.
Nasdaq will subject Salarius to a one-year Mandatory Panel Monitor following the compliance achievement.
Compliance Restored
Salarius Pharmaceuticals successfully met Nasdaq's Minimum Bid Price Requirement, marking progress toward overall compliance.
Merger Agreement
Salarius announced a merger agreement with Decoy Therapeutics, involving a business combination for new therapeutic developments.
Pipeline Advancements
Decoy Therapeutics will merge with Salarius to advance innovative peptide conjugate therapeutics, particularly in respiratory infectious diseases and GI oncology indications.
- The compliance restoration with Nasdaq's Minimum Bid Price Requirement is a significant milestone for Salarius Pharmaceuticals, reinforcing investor confidence.
- The merger agreement with Decoy Therapeutics opens doors for combined advancements in therapeutic research and development, enhancing the company's competitive edge.
The future looks promising for Salarius Pharmaceuticals as it navigates compliance requirements and embraces strategic partnerships for therapeutic advancements in the biopharmaceutical industry.